NCT00882531已完成3 期
Evaluation of the Efficacy of Isotretinoin Versus Placebo in Terms of Response Rate Among Patients Presenting Papular-pustular Rosacea Resistant to Standard Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 156
- 主要终点
- To determine numbers of patients responding to treatment for 4 months with isotretinoin (patients were considered as responders if their number of papular-pustular lesions fell by at least 90% after 4 months of treatment)
研究概览
简要总结
A national, multicentre, prospective, randomised, double-blind, phase III study in 2 parallel groups of isotretinoin versus placebo in patients presenting papular-pustular rosacea resistant to standard therapy. A non-balanced group (2 isotretinoin /1 placebo) design was selected since, given the nature of the study disease, fewer patients will receive the placebo than active isotretinoin.
Treatment duration for each patient : 4 months, with monthly evaluation Follow-up at 2 months and 4 months for patients responsive after 4 months of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients presenting papular-pustular rosacea (characterised by at least 8 lesions (papules and/or pustules)
- •resistant for at least 3 months in the last two years to standard treatment comprising systemic antibiotics (cyclins) with or without topical therapy
- •Full compliance with a two-week wash-out period for all other topical and systemic treatments for rosacea at the time of selection
- •For women of childbearing age, use of a minimum of one "effective" contraceptive method for at least one month and willingness to continue using an effective contraceptive method continuously throughout the study duration and for at least one month after the end of treatment.
- •Women of childbearing age must provide consent for pregnancy testing before the start of treatment, monthly throughout treatment and 5 weeks after the end of treatment.
- •Negative pregnancy test results from within the last 3 days (for female subjects of childbearing age)
- •No laboratory abnormalities in standard tests
- •Social Security medical cover
- •Provision of written and dated informed consent to take part in the study
排除标准
- •Patients already receiving isotretinoin for rosacea or within the last 12 months for acne
- •Patients presenting perioral dermatitis
- •Patients presenting miliary lupoid
- •Patients presenting cortisone-induced rosacea
- •Pregnant or breast-feeding women
- •Patients with repeated and habitual heavy physical activity
- •Patients with known hepatic impairment presenting cytolysis as attested by laboratory results
- •Patients presenting hyperaemia
- •Patient presenting hypervitaminosis A
- •Patients with a history of hypersensitivity to isotretinoin
- •Patients with allergy to soy oil
- •Patients on tetracycline
- •Patients with depression treated at the time of selection
- •Patients currently taking part in having taken part in another study in the last 3 months prior to inclusion in the present study
- •Patients protected by law (under guardianship or trusteeship)
- •Patients unable to comply with the study requirements
研究组 & 干预措施
Isotretinoin
Experimental
干预措施: isotretinoin (Drug)
placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
To determine numbers of patients responding to treatment for 4 months with isotretinoin (patients were considered as responders if their number of papular-pustular lesions fell by at least 90% after 4 months of treatment)
次要结局
- Change in severity of other symptoms of rosacea (burning sensation, erythema, telangiectasia, vasomotor flush, etc)
- Improvement in patients' quality of life using the reduced Skindex-France QoL scale (30 items)
- Patient satisfaction (on a visual analogue scale)
- Global treatment efficacy (global assessment)
- Relapse rates at 8 months (after start of treatment)
- Safety
研究者
相似试验
已完成
不适用
Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative studyCTRI/2017/12/010891one43
尚未招募
4 期
Effectiveness of Oral isotretinoin vs oral contraceptive in the treatment of adult acne in femaleCTRI/2024/05/068079All India institute of medical sciences
已完成
2 期
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and WrinklesPhotodamaged SkinWrinklesNCT01283464Johns Hopkins University24
招募中
不适用
Study of combination therapy by oral isotretinoin, local clobetasol, and tacrolimus in comparison to local clobetasol, and tacrolimus on patients with Frontal Fibrosing AlopeciaFrontal Fibrosing Alopecia.Lichen planopilarisIRCT2017091736173N1Tehran University of Medical Sciences34
终止
3 期
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Myelogenous LeukemiaNCT00519090Novartis Pharmaceuticals6